<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Lacosamide - SPM 927 | Erlosamide

產(chǎn)品貨號(hào)

Axon 1444 CAS [175481-36-4] MF C13H18N2O3MW 250.29 Purity: 99% Optical purity: >98% ee Soluble in water and DMSO Description Lacosamide acts by enhancing slow inactivation of voltage gated sodium channels; a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain References Certificates Categories Extra info AC Errington et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Molecular pharmacology 2008, 73 (1), 157–69.? ? AC Errington et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50 (8), 1016–1029.? ? E Ben-Menachem et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48 (7), 1308–1317. ? RL Rauck et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007, 23 (2), 150–158. ? PL Sheets et al. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther. 2008 Jul;326(1):89-99. Certificate of Analysis Material Safety Data Sheet CNS Diabetes & Metabolism Pain & Inflammation Nav1.7 Nav1.8 Unclassified Nav1.3 Na+ channel blocker; anti-convulsant Chemical name (R)-2-Acetylamino-N-benzyl-3-methoxy-propionamide Parent CAS No. [175481-36-4] Order Size Unit Price Stock 10 mg €75.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Lacosamide - SPM 927 | Erlosamide

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1444

CAS [175481-36-4]

MF C13H18N2O3
MW 250.29

Purity: 99%
Optical purity: >98% ee
Soluble in water and DMSO

Lacosamide

Description

Lacosamide acts by enhancing slow inactivation of voltage gated sodium channels; a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain

AC Errington et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Molecular pharmacology 2008, 73 (1), 157–69.?

AC Errington et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50 (8), 1016–1029.?

E Ben-Menachem et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48 (7), 1308–1317.

RL Rauck et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007, 23 (2), 150–158.

PL Sheets et al. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther. 2008 Jul;326(1):89-99.

Certificate of Analysis
Material Safety Data Sheet

CNS Diabetes & Metabolism Pain & Inflammation Nav1.7 Nav1.8 Unclassified Nav1.3

Na+ channel blocker; anti-convulsant

Chemical name

(R)-2-Acetylamino-N-benzyl-3-methoxy-propionamide

Parent CAS No.

[175481-36-4]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>